Your Health, We Care
On October 8, 2022, the United States FDA accelerated the approval of
fobatinib for the treatment of specific types of intrahepatic
cholangiocarcinoma.
It was approved for medical use in Japan in June 2023 and for medical use in
the European Union in July 2023. Not yet available in China.
